Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric Warhead
Christopher Veeck, Lennart Laube, Anke Werner…·Stephan Becker
This study develops an antiviral PROTAC targeting SARS-CoV-2 MPro using an allosteric warhead, showing LLP019 can degrade MPro and inhibit viral variants in infected cells.